LEADER 03460nam 2200493 450 001 9910717370003321 005 20221025090050.0 035 $a(CKB)2670000000429551 035 $a(NjHacI)992670000000429551 035 $a(OCoLC)815716442$z(OCoLC)810458985 035 $a(EXLCZ)992670000000429551 100 $a20221025d2012 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aUse of left ventricular assist devices as destination therapy in end-stage congestive heart failure $ea systematic review /$f[investigators, Thomas S. Rector [and four others]] 210 1$aWashington, D.C. :$cDept. of Veterans Affairs, Health Services Research & Development Service,$d[2012] 210 4$dİ2012 215 $a1 online resource (iii, 41 pages) $cillustrations 225 1 $aEvidence-based Synthesis Program 300 $a"Evidence-based synthesis program." 300 $a"May 2012." 320 $aIncludes bibliographical references. 330 3 $aHeart failure is defined as reduced ability of the heart to pump blood and maintain normal bodily function. Heart transplantation is currently the preferred treatment for end-stage heart failure but the supply of donor hearts is insufficient to meet the need and many patients are not eligible for transplantation due to age or comorbid conditions. Implantable mechanical pumps can assist the circulation of blood by the ventricles. Left ventricular assist devices (LVADs) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients awaiting transplant (a bridge to transplant) and as a last resort in patients with refractory heart failure who are not eligible for a heart transplant (destination therapy). In January 2010, the first newer generation, rotary continuous flow ventricular assist device (HeartMate II) was approved by the FDA for destination therapy. Eligibility criteria are essentially the same as those used to select patients for the pivotal clinical trial that included patients with shortness of breath and/or fatigue at rest or during minimal exertion despite treatment with optimal therapy for heart failure associated with a low ejection fraction (<25%) who were not candidates for heart transplantation due to their age or co-morbid conditions. The purpose of this report is to review the scientific evidence for use of the current generation of left ventricular assist devices as destination therapy. 410 0$aEvidence-based synthesis program (Series) 517 $aUse of left ventricular assist devices as destination therapy in end-stage congestive heart failure 606 $aHeart, Mechanical 607 $aUnited States$2fast 615 0$aHeart, Mechanical. 676 $a617.4120592 700 $aRector$b Thomas S.$0189497 702 $aRector$b Thomas S. 712 02$aQuality Enhancement Research Initiative (U.S.) 712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service, 712 02$aMinneapolis VA Health Care System (U.S.).$bVA Evidence Synthesis Program. 712 02$aEvidence-based Synthesis Program (U.S.) 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910717370003321 996 $aUse of left ventricular assist devices as destination therapy in end-stage congestive heart failure$93463910 997 $aUNINA